In a report released today, David Maris from Wells Fargo maintained a Buy rating on Jazz Pharmaceuticals (JAZZ). The company’s shares opened today at $152.50.
According to TipRanks.com, Maris has 0 stars on 0-5 star ranking scale with an average return of -11.2% and a 29.9% success rate. Maris covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amphastar Pharmaceuticals, and Kala Pharmaceuticals Inc.
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $195.63, which is a 28.3% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $201 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $184 and a one-year low of $130.15. Currently, Jazz Pharmaceuticals has an average volume of 463.9K.
Based on the recent corporate insider activity of 91 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Rick Winningham, a Director at JAZZ sold 16,639 shares for a total of $2,931,292.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
